Medical treatment of diabetic retinopathy with somatostatin analogues

Bibliography

• AIELLO LP, GARDNER TW, KING GL et al.: Diabetic retinopathy. Diabetes Care (1998) 21(1):143-156.
   PubMed Web of Science ®Google Scholar
• DRS: Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology (1981) 88(7):583-600.
   PubMed Web of Science ®Google Scholar
• ETDRS: Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 98(Suppl. 5):766-785.
   PubMed Web of Science ®Google Scholar
• DCCT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. (1993) 329(14):977-986.
   PubMed Web of Science ®Google Scholar
• DCCT: Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med. (2000) 342(6):381-389.
   PubMed Web of Science ®Google Scholar
• UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352(9131):837-853.
   PubMed Web of Science ®Google Scholar
• KLEIN R, KLEIN BE, MOSS SE, CRUICKSHANKS KJ: The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch. Ophthalmol. (1994) 112(9):1217-1228.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M: Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414(6865):813-820.
   PubMed Web of Science ®Google Scholar
• BROWNLEE M, CERAMI A, VLASSARA H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab. Rev. (1988) 4(5):437-451.
   PubMed Web of Science ®Google Scholar
• KOWLURU RA: Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. (2001) 38(4):179-185.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO S, KAWANO H, HOKAMAKI J et al.: Increased plasma levels of thioredoxin in patients with glucose intolerance. Intern. Med. (2005) 44(11):1127-1132.
   PubMed Web of Science ®Google Scholar
• NAKAMURA J, KASUYA Y, HAMADA Y et al.: Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia (2001) 44(4):480-487.
   PubMed Web of Science ®Google Scholar
• SHEETZ MJ, KING GL: Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA (2002) 288(20):2579-2588.
   PubMed Web of Science ®Google Scholar
• SPRANGER J, PFEIFFER AF: New concepts in pathogenesis and treatment of diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes (2001) 109(Suppl. 2):S438-S450.
   PubMed Web of Science ®Google Scholar
• XIA P, INOGUCHI T, KERN TS et al.: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes (1994) 43(9):1122-1129.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, BURSELL SE, CLERMONT A et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes (1997) 46(9):1473-1480.
   PubMed Web of Science ®Google Scholar
• WILLIAMS B, GALLACHER B, PATEL H, ORME C: Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes (1997) 46(9):1497-1503.
   PubMed Web of Science ®Google Scholar
• CABALLERO S Jr, SENGUPTA N, LICALZI S et al.: Endothelial precursor cells exhibit robust reparative function of acellular capillaries in the retina. Invest. Ophthalmol. Vis. Sci. (2006) 47(5):3525-.
   Google Scholar
• WAY KJ, KATAI N, KING GL: Protein kinase C and the development of diabetic vascular complications. Diabet. Med. (2001) 18(12):945-959.
   PubMed Web of Science ®Google Scholar
• URBICH C, DIMMELER S: Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. (2005) 67(5):1672-1676.
   PubMed Web of Science ®Google Scholar
• VASA M, FICHTLSCHERER S, ADLER K et al.: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation (2001) 103(24):2885-2890.
   PubMed Web of Science ®Google Scholar
• GERICH JE: Rationale for inhibition of growth hormone secretion in the management of the diabetic patient. Scand. J. Gastroenterol. Suppl. (1986) 119:154-157.
   PubMedGoogle Scholar
• BRUNS C, WECKBECKER G, RAULF F, LUBBERT H, HOYER D: Characterization of somatostatin receptor subtypes. Ciba Found. Symp. (1995) 190:89-101 (Discussion 101-110).
   PubMedGoogle Scholar
• CRISTIANI R, FONTANESI G, CASINI G et al.: Expression of somatostatin subtype 1 receptor in the rabbit retina. Invest. Ophthalmol. Vis. Sci. (2000) 41(10):3191-3199.
   PubMed Web of Science ®Google Scholar
• CRISTIANI R, PETRUCCI C, DAL MONTE M, BAGNOLI P: Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res. (2002) 936(1-2):1-14.
   PubMed Web of Science ®Google Scholar
• VAN HAGEN PM, BAARSMA GS, MOOY CM et al.: Somatostatin and somatostatin receptors in retinal diseases. Eur. J. Endocrinol. (2000) 143(Suppl. 1):S43-S51.
   PubMed Web of Science ®Google Scholar
• LAMBOOIJ AC, KUIJPERS RW, VAN LICHTENAUER-KALIGIS EG et al.: Somatostatin receptor 2A expression in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2000) 41(8):2329-2335.
   PubMed Web of Science ®Google Scholar
• KLISOVIC DD, O’DORISIO MS, KATZ SE et al.: Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest. Ophthalmol. Vis. Sci. (2001) 42(10):2193-2201.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ C, CARRASCO E, CASAMITJANA R et al.: Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care (2005) 28(8):1941-1947.
   PubMed Web of Science ®Google Scholar
• PARK S, KAMEGAI J, JOHNSON TA, FROHMAN LA, KINEMAN RD: Modulation of pituitary somatostatin receptor subtype (SST1-5) messenger. Endocrinology (2000) 141(10):3556-3563.
   PubMed Web of Science ®Google Scholar
• PLEWE G, BEYER J, KRAUSE U, NEUFELD M, DEL POZO E: Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet (1984) 2(8406):782-784.
   PubMed Web of Science ®Google Scholar
• RACINE MS, BARKAN AL: Somatostatin analogs in medical treatment of acromegaly. Endocrine (2003) 20(3):271-278.
   PubMed Web of Science ®Google Scholar
• BLANCHIN M, JAMES-DEIDIER A, CHAUMET-RIFFAUD PD, CHAYVIALLE JA: [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study]. Presse Med. (1992) 21(15):697-702.
   PubMed Web of Science ®Google Scholar
• POULSEN JE: Recovery from retinopathy in a case of diabetes with Simmonds’ disease. Diabetes (1953) 2(1):7-12.
   PubMed Web of Science ®Google Scholar
• POZO J, MARTOS-MORENO GA, BARRIOS V, ARGENTE J: The IGF system in childhood: physiology and clinical implications. J. Endocrinol. Invest. (2005) 28(5 Suppl.):38-42.
   PubMedGoogle Scholar
• LEE J, MENON RK: Molecular defects in the growth hormone-IGF axis. Indian J. Pediatr. (2005) 72(2):145-148.
   PubMedGoogle Scholar
• ISAKSSON O: GH, IGF-I, and growth. J. Pediatr. Endocrinol. Metab. (2004) 17(Suppl. 4):1321-1326.
   PubMed Web of Science ®Google Scholar
• YAKAR S, PENNISI P, WU Y, ZHAO H, LEROITH D: Clinical relevance of systemic and local IGF-I. Endocr. Dev. (2005) 9:11-16.
   PubMedGoogle Scholar
• MERIMEE TJ, ZAPF J, FROESCH ER: Insulin-like growth factors in the fed and fasted states. J. Clin. Endocrinol. Metab. (1982) 55(5):999-1002.
   PubMed Web of Science ®Google Scholar
• ALZAID AA, DINNEEN SF, MELTON LJ III, RIZZA RA: The role of growth hormone in the development of diabetic retinopathy. Diabetes Care (1994) 17(6):531-534.
   PubMed Web of Science ®Google Scholar
• LUNDBAEK K, JENSEN VA, OLSEN TS et al.: Growth hormone and diabetic angiopathy. Lancet (1970) 2(7670):472.
   PubMedGoogle Scholar
• ORSKOV H, JOHANSEN K: Serum-insulin in remission of juvenile diabetes. Lancet (1968) 2(7577):1081.
   PubMedGoogle Scholar
• LUFT R, OLIVECRONA H, IKKOS D, KORNERUP T, LJUNGGREN H: Hypophysectomy in man; further experiences in severe diabetes mellitus. Br. Med. J. (1955) 2(4942):752-756.
   PubMed Web of Science ®Google Scholar
• LUFT R, OLIVECRONA H, SJOGREN B: Hypophysectomy in man: experiences in severe diabetes mellitus. J. Clin. Endocrinol. Metab. (1955) 15(4):391-408.
   PubMed Web of Science ®Google Scholar
• SHARP PS, FALLON TJ, BRAZIER OJ et al.: Long-term follow-up of patients who underwent yttrium-90 pituitary. Diabetologia (1987) 30(4):199-207.
   PubMed Web of Science ®Google Scholar
• WRIGHT AD, KOHNER EM, OAKLEY NW et al.: Serum growth hormone levels and the response of diabetic retinopathy to. Br. Med. J. (1969) 2(5653):346-348.
   PubMed Web of Science ®Google Scholar
• MERIMEE TJ: A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N. Engl. J. Med. (1978) 298(22):1217-1222.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS JD, DYMOCK IW, DAVIES EW, HILL DW, WILLIAMS R: Occurrence and prevalence of diabetic retinopathy in hemochromatosis. Diabetes (1971) 20(11):766-770.
   PubMed Web of Science ®Google Scholar
• DILLS DG, MOSS SE, KLEIN R, KLEIN BE: Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes (1991) 40(12):1725-1730.
   PubMed Web of Science ®Google Scholar
• GERHARDINGER C, McCLURE KD, ROMEO G, PODESTA F, LORENZI M: IGF-I mRNA and signaling in the diabetic retina. Diabetes (2001) 50(1):175-183.
   PubMed Web of Science ®Google Scholar
• SIMO R, HERNANDEZ C, SEGURA RM et al.: Free insulin-like growth factor 1 in the vitreous fluid of diabetic. Clin. Sci. (Lond.) (2003) 104(3):223-230.
   PubMed Web of Science ®Google Scholar
• LOWE WL Jr, FLORKIEWICZ RZ, YOREK MA, SPANHEIMER RG, ALBRECHT BN: Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism (1995) 44(8):1038.
   Google Scholar
• AVERBUKH E, WEISS O, HALPERT M et al.: Gene expression of insulin-like growth factor-I, its receptor and binding. Metabolism (1998) 47(11):1331-1336.
   PubMed Web of Science ®Google Scholar
• SPOERRI PE, ELLIS EA, TARNUZZER RW, GRANT MB: Insulin-like growth factor: receptor and binding proteins in human retinal. Growth Horm. IGF Res. (1998) 8(2):125-132.
   PubMed Web of Science ®Google Scholar
• CHANTELAU E, EGGERT H, SEPPEL T, SCHONAU E, ALTHAUS C: Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac’s syndrome. Br. J. Ophthalmol. (1997) 81(2):169-170.
   PubMed Web of Science ®Google Scholar
• CHANTELAU E: Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br. J. Ophthalmol. (1998) 82(7):725-730.
   PubMed Web of Science ®Google Scholar
• DANEMAN D, LOBES LA, BECKER DJ, DRASH AL: Diabetic retinopathy in Mauriac’s syndrome. Paradoxical deterioration with improved metabolic control. Retina (1981) 1(2):84-87.
   PubMedGoogle Scholar
• DAVIS MD, FISHER MR, GANGNON RE et al.: Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18. Invest. Ophthalmol. Vis. Sci. (1998) 39(2):233-252.
   PubMed Web of Science ®Google Scholar
• HYER SL, SHARP PS, BROOKS RA, BURRIN JM, KOHNER EM: Serum IGF-1 concentration in diabetic retinopathy. Diabet. Med. (1988) 5(4):356-360.
   PubMed Web of Science ®Google Scholar
• POULAKI V, QIN W, JOUSSEN AM et al.: Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier. J. Clin. Invest. (2002) 109(6):805-815.
   PubMed Web of Science ®Google Scholar
• KONDO T, VICENT D, SUZUMA K et al.: Knockout of insulin and IGF-1 receptors on vascular endothelial cells. J. Clin. Invest. (2003) 111(12):1835-1842.
   PubMed Web of Science ®Google Scholar
• ADAMS RL, ADAMS IP, LINDOW SW, ATKIN SL: Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin. Endocrinol. (Oxf.) (2004) 61(4):431-436.
   PubMed Web of Science ®Google Scholar
• BALDYSIAK-FIGIEL A, LANG GK, KAMPMEIER J, LANG GE: Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J. Endocrinol. (2004) 180(3):417-424.
   PubMed Web of Science ®Google Scholar
• GRANT MB, CABALLERO S, MAMES RN, SHAPIRO G: Designer drugs: peptidomimetics of somatostatin specifically target ocular neovascularization. Invest. Ophthalmol. Vis. Sci. (2005) 46(5):4171-.
   Google Scholar
• GRANT MB, CABALLERO S, MILLARD WJ: Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul. Pept. (1993) 48(1-2):267-278.
   PubMed Web of Science ®Google Scholar
• SPRAUL CW, BALDYSIAK-FIGIEL A, LANG GK, LANG GE: Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch. Clin. Exp. Ophthalmol. (2002) 240(3):227-231.
   PubMed Web of Science ®Google Scholar
• WOLTERING EA: Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother. Radiopharm. (2003) 18(4):601-609.
   PubMed Web of Science ®Google Scholar
• ADAMS RL, ADAMS IP, LINDOW SW, ZHONG W, ATKIN SL: Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br. J. Cancer (2005) 92(8):1493-1498.
   PubMed Web of Science ®Google Scholar
• WATSON JC, BALSTER DA, GEBHARDT BM et al.: Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer (2001) 85(2):266-272.
   PubMed Web of Science ®Google Scholar
• WILSON SH, DAVIS MI, CABALLERO S, GRANT MB: Modulation of retinal endothelial cell behaviour by insulin-like growth Factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm. IGF Res. (2001) 11(Suppl. A):S53-S59.
   PubMedGoogle Scholar
• PATEL YC: Somatostatin and its receptor family. Front. Neuroendocrinol. (1999) 20(3):157-198.
   PubMed Web of Science ®Google Scholar
• YANG L, BERK SC, ROHRER SP et al.: Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. USA (1998) 95(18):10836-10841.
   PubMed Web of Science ®Google Scholar
• SMITH LE, KOPCHICK JJ, CHEN W et al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276(5319):1706-1709.
   PubMed Web of Science ®Google Scholar
• HIGGINS RD, YAN Y, SCHRIER BK: Somatostatin analogs inhibit neonatal retinal neovascularization. Exp. Eye Res. (2002) 74(5):553-559.
   PubMed Web of Science ®Google Scholar
• AVERBUKH E, HALPERT M, YANKO R et al.: Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat. Int. J. Exp. Diabetes Res. (2000) 1(1):39-47.
   PubMedGoogle Scholar
• NAVASCUES I, GIL J, PASCAU C et al.: Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in Type I diabetes mellitus. Horm. Res. (1988) 29(2-3):92-94.
   PubMed Web of Science ®Google Scholar
• HYER SL, SHARP PS, BROOKS RA, BURRIN JM, KOHNER EM: Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol. (Copenh.) (1989) 120(2):187-194.
   PubMedGoogle Scholar
• KIRKEGAARD C, NORGAARD K, SNORGAARD O et al.: Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol. (Copenh.) (1990) 122(6):766-772.
   PubMedGoogle Scholar
• MALLET B, VIALETTES B, HAROCHE S et al.: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab. (1992) 18(6):438-444.
   PubMed Web of Science ®Google Scholar
• CLEMENS A, KLEVESATH MS, HOFMANN M et al.: Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism (1999) 48(10):1236-1240.
   PubMed Web of Science ®Google Scholar
• GRANT MB, MAMES RN, FITZGERALD C et al.: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care (2000) 23(4):504-509.
   PubMed Web of Science ®Google Scholar
• BOEHM BO, LANG GK, JEHLE PM, FELDMAN B, LANG GE: Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res. (2001) 33(5):300-306.
   PubMed Web of Science ®Google Scholar
• ROHRER SP, BIRZIN ET, MOSLEY RT et al.: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 282(5389):737-740.
   PubMed Web of Science ®Google Scholar